Non-Motor Symptoms and Therapeutic Approaches in Parkinson's Disease

Parkinson’s disease (PD) is traditionally recognised by its motor impairments, but non-motor symptoms often precede or accompany movement deficits and have a profound impact on quality of life. These features encompass neuropsychiatric manifestations such as depression, anxiety and cognitive decline; autonomic disturbances including orthostatic hypotension, gastrointestinal dysmotility and urinary dysfunction; sleep disorders such as rapid eye movement sleep behaviour disorder and excessive daytime somnolence; sensory complaints including pain and olfactory loss; and pervasive fatigue. Their multifactorial origins involve α-synuclein aggregation, dopaminergic and non-dopaminergic neurotransmitter imbalances, neuroinflammation and alterations in peripheral systems such as the gut–brain axis. Standard dopaminergic medications may ameliorate some non-motor manifestations, but efficacy is variable and side-effects frequent. Non-pharmacological interventions—chiefly cognitive rehabilitation, exercise and dietary modulation—offer complementary benefits. Emerging approaches target underlying mechanisms: immunomodulation to reduce microglial activation, gene therapies to correct hereditary forms or modulate α-synuclein expression, neurotrophic factors to support neuronal survival, and advanced drug-delivery systems to enhance central nervous system bioavailability while minimising systemic toxicity. Integrated, personalised care models emphasise early identification of non-motor signs, multidisciplinary management and patient empowerment to optimise function and wellbeing.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Non-Motor Symptoms and Therapeutic Approaches in Parkinson's Disease publication trend

The graph below shows the total number of articles in non-motor symptoms and therapeutic approaches in parkinson's disease across all publications each year (not limited to Nature Index journals).

Technical terms

α-Synuclein: Neuronal protein prone to misfolding into aggregates that disrupt cellular function and contribute to PD pathology.

Dysautonomia: Dysfunction of the autonomic nervous system causing symptoms such as orthostatic hypotension and gastrointestinal motility disorders.

Neuroinflammation: Activation of glial cells and release of cytokines within the central nervous system that exacerbate neurodegeneration.

Nanodelivery system: Engineered nanoparticles designed to transport therapeutic agents across biological barriers to target specific tissues.

References

1. Treatment Options for Motor and Non-Motor Symptoms of Parkinson’s Disease. Biomolecules (2021).
2. Proactive and Integrated Management and Empowerment in Parkinson’s Disease: Designing a New Model of Care. Parkinson's Disease (2020).
3. Neuroinflammation represents a common theme amongst genetic and environmental risk factors for Alzheimer and Parkinson diseases. Journal of Neuroinflammation (2022).
4. The understanding of Parkinson's disease through genetics and new therapies. Brain and Behavior (2022).
5. Importance of Nanoparticles for the Delivery of Antiparkinsonian Drugs. Pharmaceutics (2021).